We’re proud to be a leader in the treatment of B-cell malignancies. And currently, we’re seeking to do even more. By broadening our scientific discovery efforts across new technologies, we are pursuing our goal of developing cell therapies that not only continue to advance safety and efficacy, but are also able to treat a broader range of cancers.
As we continue to move forward in addressing hematological malignancies, we are studying cell therapy for other B-cell malignancies and hematologic malignancies, including mantle cell lymphoma (MCL), adult acute lymphoblastic leukemia (ALL), follicular and marginal zone lymphoma, and chronic lymphocytic leukemia (CLL).
At Kite, we are always working to expand the potential of our cell therapy work. That’s why we’ve partnered with leading organizations to further our research and development of TCR constructs to identify targets inside the cancer cells of solid tumors, such as human papillomavirus (HPV)-associated cancers, so that we can start to address certain types of solid tumors in the future.
Current CAR T products are autologous, requiring customized, on-demand manufacturing of each patient’s individualized product, which can result in 2- to 3-week turnaround times, high costs, and capacity constraints. To overcome these challenges, Kite is developing “off-the-shelf” allogeneic CAR T cell products using gene editing technology. The allogeneic approach simplifies manufacturing logistics to enable patients to receive treatment faster, and expands access so more patients can receive potentially lifesaving therapy.
Certain technologies, agents, and/or uses described above are investigational. Their safety and efficacy have not been established, and they have not been approved by the US Food and Drug Administration or other regulatory authorities. There is no guarantee that Kite will commercialize these technologies, agents, and/or uses.